Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Rufu Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0009-0009-3479-8595; OpenAlex author ID A5030692575. Sources: OpenAlex.

Their work

Papers
31 (first author 1, last author 11)
Trials
0
Grants
0
Labs led
2
Collaborators
127
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 3 papers · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 3 papers · 2020: 2 papers · 2021: 5 papers · 2022: 1 paper · 2023: 5 papers · 2024: 2 papers · 2025: 5 papers · 2026: 2 papers

Papers 31

  1. USP20 promotes CD8+ T cell exhaustion and impairs KRAS G12D inhibitor efficacy by orchestrating cholesterol metabolism and autophagy in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2026-338277↗
  2. Correction: circNFIB1 inhibits lymphangiogenesis and lymphatic metastasis via the miR-486-5p/PIK3R1/VEGF-C axis in pancreatic cancer. Co-author DOI 10.1186/s12943-026-02730-6↗
  3. Integrated single-cell and spatial transcriptomics uncover distinct cellular subtypes involved in neural invasion in pancreatic cancer. Co-author DOI 10.1016/j.ccell.2025.06.020↗
  4. Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for untreated advanced or metastatic pancrea… Co-author DOI 10.1186/s12916-025-04234-4↗
  5. LNP-enclosed NamiRNA inhibits pancreatic cancer proliferation and migration via dual pathways. Last author DOI 10.1186/s12951-025-03550-4↗
  6. Treatment options in patients with pancreatic cancer: A 10-year multicenter epidemiological investigation in China. Co-author DOI 10.4251/wjgo.v17.i8.106447↗
  7. RBMS1-mediates the biogenesis of circNFIB promotes perineural invasion of pancreatic ductal adenocarcinoma via the L1CAM/MAPK pathway. Last author DOI 10.7150/thno.112753↗
  8. Nudt21-mediated alternative polyadenylation of MZT1 3'UTR contributes to pancreatic cancer progression. Co-author DOI 10.1016/j.isci.2024.108822↗
  9. KHSRP Stabilizes m6A-Modified Transcripts to Activate FAK Signaling and Promote Pancreatic Ductal Adenocarcinoma Progression. Co-author DOI 10.1158/0008-5472.can-24-0927↗
  10. LncRNA BCAN-AS1 stabilizes c-Myc via N6-methyladenosine-mediated binding with SNIP1 to promote pancreatic cancer. Co-author DOI 10.1038/s41418-023-01225-x↗
  11. Super-enhancer RNA m6A promotes local chromatin accessibility and oncogene transcription in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41588-023-01568-8↗
  12. N 6-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-22-3346↗
  13. Mutant KRAS Mediates circARFGEF2 Biogenesis to Promote Lymphatic Metastasis of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/0008-5472.can-22-3997↗
  14. HNF1A regulates oxaliplatin resistance in pancreatic cancer by targeting 53BP1. Last author DOI 10.3892/ijo.2023.5493↗
  15. KRAS mutant-driven SUMOylation controls extracellular vesicle transmission to trigger lymphangiogenesis in pancreatic cancer. Last author DOI 10.1172/jci157644↗
  16. Correction: Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer. Last author DOI 10.1038/s41419-021-03420-5↗
  17. LINC00842 inactivates transcription co-regulator PGC-1α to promote pancreatic cancer malignancy through metabolic remodelling. Co-author DOI 10.1038/s41467-021-23904-4↗
  18. N6 -methyladenosine-Mediated Upregulation of WTAPP1 Promotes WTAP Translation and Wnt Signaling to Facilitate Pancreatic Cancer Progression. Co-author DOI 10.1158/0008-5472.can-21-0494↗
  19. Inflammatory cytokine-regulated tRNA-derived fragment tRF-21 suppresses pancreatic ductal adenocarcinoma progression. Co-author DOI 10.1172/jci148130↗
  20. Genome-wide identification and characterization of circular RNA m6A modification in pancreatic cancer. Co-author DOI 10.1186/s13073-021-01002-w↗
  21. LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jcmgh.2020.06.009↗
  22. lncRNA-PLACT1 sustains activation of NF-κB pathway through a positive feedback loop with IκBα/E2F1 axis in pancreatic cancer. Last author DOI 10.1186/s12943-020-01153-1↗
  23. Experts' consensus on intraoperative radiotherapy for pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.01.038↗
  24. Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF-β1/smad2/3 axis in pancreatic cancer. Last author DOI 10.1016/j.canlet.2019.06.005↗
  25. Excessive miR-25-3p maturation via N6-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression. Co-author DOI 10.1038/s41467-019-09712-x↗
  26. Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer. Last author DOI 10.1038/s41419-018-1104-x↗
  27. The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreati… Co-author DOI 10.3892/ijo.2015.3316↗
  28. Analysis of global gene expression profiles suggests a role of acute inflammation in type 3C diabetes mellitus caused by pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00125-014-3481-8↗
  29. Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. Co-author DOI 10.1097/md.0000000000001345↗
  30. Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resectable pancreatic head cancer? A consensus … First author DOI 10.3892/ijo.2015.3128↗
  31. Pancreatic stellate cells promotes the perineural invasion in pancreatic cancer. Last author DOI 10.1016/j.mehy.2012.03.017↗

Closest collaborators

The 25 strongest of 127 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Quanbo Zhou · 10 shared papers, 2012–2024 · strength 1.20
  2. Jian Zheng · 9 shared papers, 2019–2024 · strength 1.05
  3. Jialiang Zhang · 9 shared papers, 2019–2024 · strength 1.05
  4. Dongxin Lin · 9 shared papers, 2019–2024 · strength 1.05
  5. Xudong Huang · 8 shared papers, 2021–2024 · strength 0.98
  6. Lusheng Wei · 8 shared papers, 2018–2025 · strength 0.89
  7. Jiachun Su · 8 shared papers, 2019–2023 · strength 0.89
  8. Lingxing Zeng · 7 shared papers, 2021–2024 · strength 0.88
  9. Shaoping Zhang · 7 shared papers, 2021–2024 · strength 0.88
  10. Shangyou Zheng · 8 shared papers, 2015–2023 · strength 0.84
  11. Changhao Chen · 6 shared papers, 2015–2026 · strength 0.83
  12. Zhihua Li · 6 shared papers, 2015–2026 · strength 0.81
  13. Dingwen Zhang · 4 shared papers, 2022–2025 · strength 0.81
  14. Yuming Luo · 4 shared papers, 2020–2026 · strength 0.69
  15. Yanfen Zheng · 6 shared papers, 2019–2023 · strength 0.61
  16. Yao Kong · 3 shared papers, 2022–2026 · strength 0.59
  17. Yu Zhou · 2 shared papers, 2024–2025 · strength 0.54
  18. Junge Deng · 5 shared papers, 2021–2023 · strength 0.54
  19. Rui Li · 4 shared papers, 2021–2024 · strength 0.54
  20. Jiabin Yang · 3 shared papers, 2022–2024 · strength 0.54
  21. Ying Ye · 5 shared papers, 2019–2023 · strength 0.51
  22. Huilin Ye · 6 shared papers, 2015–2021 · strength 0.50
  23. Guolin Li · 5 shared papers, 2018–2021 · strength 0.46
  24. Guandi Wu · 4 shared papers, 2021–2023 · strength 0.44
  25. Zhixiang Zuo · 4 shared papers, 2019–2023 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.